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MATTERS ARISING
Reply to ‘Hypothermic machine perfusion
before viability testing of previously discarded
human livers’
Hynek Mergental 1,2,3✉, Richard W. Laing1,2,3, Simon C. Afford2,3 & Darius F. Mirza 1,2,3
REPLYING TO Otto B. van Leeuwen et al. Nature Communications https://doi.org/10.1038/s41467-021-21182-8 (2021)
We read with interest the comments regarding ourVITTAL study report, submitted to Nature Commu-nications by Dr. van Leeuwen and colleagues1, and we
would like to take the opportunity to clarify the issues they
highlighted regarding our trial novelty, the tested viability criteria,
and use of the end-ischaemic normothermic perfusion alone2.
Firstly, we want to thank the authors for their compliments
acknowledging the challenges of performing complex, high-risk liver
transplant trials, as this context is important to the interpretation of
the results of such research. Machine perfusion is a rapidly devel-
oping field that changes many aspects of transplantation medicine,
and in the particular context of normothermic liver perfusion
(NMP), minimises ischaemia reperfusion injury, allows significantly
longer organ preservation, enables liver viability testing, and pro-
vides opportunity for therapeutic interventions3–6. The assessment
of liver viability was pioneered by several groups, who indepen-
dently developed different protocols for assessing transplantability,
taking the risks of exploring the boundaries of liver utilisation in the
era of closely scrutinised programmes’ outcomes7–9. While the
potential benefits of NMP compared to static cold storage are many,
the added cost and complexity of the procedure means that the
transplant community looks for compelling clinical evidence to
justify its use10.
Our group completed the proof-of-concept transplant series
with discarded livers in 2015, and immediately proceeded to
further rigorous testing with updated viability criteria within a
clinical trial framework7,11. The VITTAL study linked primary
endpoints of liver recovery rate and the 90-day graft survival.
Worldwide, the risks of dying on the waiting list are significantly
higher than the mortality after transplantation, and the organ
utilisation parameters were used as proxy measures for access to
the transplant treatment12,13. The inclusion of suboptimal livers
in machine perfusion trials has been widely accepted by the
transplant community, as these organs benefit most from the use
of this novel technology14,15. Conducting studies with discarded
livers in this context brings the greatest benefit to the patients
from the local waiting list perspective, although some critics may
view this particular inclusion criterion as being vague or
subjective.
The motives for donor livers not being used are usually mul-
tifactorial, but can be grouped according to reasons relating to the
donor, the recipient or logistics. VITTAL aimed to explore the
limits of the highest-risk donor liver utilisation and intended to
include livers discarded due to donor-related factors only, to allow
an unambiguous reproducibility of its findings. We addressed the
major challenge of achieving this objective by using a two-tier
process of liver inclusion. However, the study design also needed
to ensure recipient safety and address the ethical dilemma of not
including discarded livers of better quality than required for trial
inclusion (which would very likely meet the viability criteria and
lead to superior post-transplant results), as outlined in the
manuscript Supplementary material.
The time lag between pilot clinical findings and their valida-
tion by a prospective trial is the major pitfall of producing high-
level evidence in this rapidly evolving field. This means that
today’s discovery may take an average of 4–5 years to be pub-
lished in a peer-reviewed journal, and this can take significantly
longer if the project were funded by an independent body or
required a multi-centre design3,14,16. The issue raised by Dr. van
Leeuwen and colleagues regarding the use of viability criteria
without considering bile production and composition is valid,
and if we were designing the trial today we would have included
those. VITTAL was designed, however, in 2015, and the patients
enroled in the 16-month period from November 2016 to Feb-
ruary 201811, when the significance of bile composition for the
development of non-anastomotic biliary strictures (NAS) in
livers donated after circulatory death (DCD) was not
yet known8,9,17. While DCD donors may represent the pool of
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organs with the greatest potential for future expansion, on the
global scale this remains a niche area as >90% of liver transplants
in the Western world are currently performed with livers
donated after brain death (DBD)12,15,18. As a result, a large
majority of livers are underutilised due to steatosis or logistical
reasons (e.g., suboptimal livers that might be usable, but the
excessive projected cold ischaemic time precludes their use).
Considering the exceedingly low incidence of non-anastomotic
biliary strictures in DBD livers, the testing of viability focused on
hepatocellular function might be a preferable option19.
Adoption and implementation of machine perfusion into the
liver transplantation pathway might have several indications, e.g., to
avoid the devastating consequences of liver primary non-function
and severe early dysfunction. The end-ischaemic NMP viability
assessment used in VITTAL was intended as a diagnostic tool to
select transplantable livers from the pool of the highest-risk donors.
The study demonstrated that 7 out of 10 livers can be safely
transplanted with 100% 90-day graft survival. When we applied the
Groningen viability criteria to the VITTAL cohort of 31 livers
discarded by all UK transplant centres that met the pre-defined
high-risk criteria, only one liver was deemed to be transplantable.
This organ remained functioning at 24-months follow up, and
while this proves that the criteria have high specificity to predict
NAS, the sensitivity to predict graft loss within 90-days appears to
be relatively low. Robust modelling would be required to quantify
the net benefits of the improved access to transplantation on
waiting list mortality, after deduction of the added patients needing
re-transplantation for non-anastomotic biliary strictures. The 100%
actuarial post-transplant patient survival in both the authors’ and
our own series, however, suggests a clear benefit to receiving a
transplant compared to remaining on the waiting list2,9. More
research is needed to establish whether DBD and DCD livers should
be assessed using the same or different criteria, and this is an
ongoing interest of ours.
The incidence of NAS in DCD livers enrolled in the trial was
nevertheless higher than anticipated. VITTAL was not powered to
evaluate post-transplant biliary complications, and the only specific
inclusion criterion for DCD livers was excessive donor warm
ischaemia (defined as the period between the systolic blood pressure
<50mmHg to aortic perfusion >30min). We were transparent in
reporting the study outcomes, including the results of per-protocol
performed magnetic resonance cholangiopancreatography scans.
Our key messages are that end-ischaemic NMP did not cause biliary
problems even in very marginal DBD livers, and that this type of
perfusion did not appear to prevent development of non-
anastomotic biliary strictures in high-risk DCD grafts; of the lost
livers, one graft was exposed to 40min of donor warm ischaemia,
and the other two came from 69-year-old donors.
The Groningen group has a long track record in research on
biliary complications in DCD transplants, and we expect their
ongoing randomised trial will provide important evidence on the
choice of optimal strategies to prevent NAS17,20,21. We eagerly
await the results, as most of the studies published to date kept the
donor warm ischaemia within the 30-min safety zone9,22,23. We
appreciate the important technical remark regarding the benefits
of using small diameter biliary catheters and the importance of
avoiding technical issues, leading to a presumed lack of bile
production24,25.
To conclude, the VITTAL trial demonstrated that objective
assessment of high-risk donor livers can allow safe utilisation of
up to 70% of currently discarded organs while achieving 100% 90-
day graft survival. The study design introduced for the first time
rigorous and reproducible high-risk inclusion criteria. While our
viability measures achieved high-liver recovery rates, the addition
of bile assessment might improve diagnostic accuracy regarding
non-anastomotic biliary strictures in DCD livers.
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